ACS CAN Comments on FDA Draft Guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.